Jacek Jassem

Jacek Jassem

17 Smoluchowskiego St
Gdansk, PM 80214, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 357 publications

Mutational landscapes of brain metastases across various histological subtypes of lung cancer.

Mutational landscapes of brain metastases across various histological subtypes of lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 27, 2025

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 26, 2025

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2- advanced breast cancer: A multicenter retrospective study.

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2- advanced breast cancer: A multicenter retrospective study.

Journal: Breast (Edinburgh, Scotland)

Published: October 12, 2025

Prospects for implementing the European Code of Cancer Practice: Lessons from Poland.

Prospects for implementing the European Code of Cancer Practice: Lessons from Poland.

Journal: Health policy (Amsterdam, Netherlands)

Published: September 25, 2025

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 27, 2025

Polish consensus on smoking cessation intervention within lung cancer screening 1.

Polish consensus on smoking cessation intervention within lung cancer screening 1.

Journal: Archives of medical science : AMS

Published: July 29, 2025

Genetic composition and evolutionary trajectories of brain metastasis in non-small-cell lung cancer.

Genetic composition and evolutionary trajectories of brain metastasis in non-small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 05, 2025

TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation.

TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation.

Journal: Translational lung cancer research

Published: June 17, 2025

Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials.

Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 30, 2025

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Journal: Nature cancer

Published: April 23, 2025

Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma.

Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma.

Journal: Current oncology reports

Published: April 22, 2025

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.

Journal: JAMA

Published: January 30, 2025

Showing 1-12 of 357

Last Updated: 09/26/2026